Global News and Digital Insights
for the Healthcare Industry

AstraZeneca, Daiichi’s Enhertu bags instant approval for HER2-low breast cancer use

AstraZeneca and Daiichi become the first companies to have developed a therapy aimed at treating metastatic breast cancer that manifests low level of HER2, a new category that was once classified under HER2-negative. AstraZeneca’s Enhertu has received FDA’s approval as the trial shows that it cuts down the risk of tumour progression by 50%. Enhertu shows various benefits after one session of chemotherapy of metastatic tumour.

Read More from FiercePharma